Polycythemia Vera-Pipeline Review, H1 2016

Polycythemia Vera-Pipeline Review, H1 2016


  • Products Id :- GMDHC7756IDB
  • |
  • Pages: 75
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Polycythemia Vera-Pipeline Review, H1 2016', provides an overview of the Polycythemia Vera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera

The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects

The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Polycythemia Vera

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Polycythemia Vera Overview 7

Therapeutics Development 8

Pipeline Products for Polycythemia Vera-Overview 8

Polycythemia Vera-Therapeutics under Development by Companies 9

Polycythemia Vera-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Polycythemia Vera-Products under Development by Companies 13

Polycythemia Vera-Companies Involved in Therapeutics Development 14

Bristol-Myers Squibb Company 14

Galena Biopharma, Inc. 15

Gilead Sciences, Inc. 16

Italfarmaco S.p.A. 17

Karus Therapeutics Limited 18

Merck & Co., Inc. 19

miRagen Therapeutics, Inc. 20

Nerviano Medical Sciences S.r.l. 21

Novartis AG 22

PharmaEssentia Corporation 23

Polycythemia Vera-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

anagrelide hydrochloride CR-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

dasatinib-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

givinostat-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

idelalisib-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

KA-1463-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

M-009-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

M-012-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

MGN-4893-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

MRLB-11055-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

NMSP-113-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ropeginterferon alfa-2b-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

sonidegib phosphate-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Polycythemia Vera-Recent Pipeline Updates 56

Polycythemia Vera-Dormant Projects 67

Polycythemia Vera-Discontinued Products 68

Polycythemia Vera-Product Development Milestones 69

Featured News & Press Releases 69

Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 69

Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition 69

Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera 70

Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 71

Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera 72

Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera 72

Feb 17, 2011: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for Treatment of Polycythemia Vera 73

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Figures

Number of Products under Development for Polycythemia Vera, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 11

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Top 10 Targets, H1 2016 25

Number of Products by Stage and Top 10 Targets, H1 2016 25

Number of Products by Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Routes of Administration, H1 2016 29

Number of Products by Stage and Routes of Administration, H1 2016 29

Number of Products by Molecule Types, H1 2016 31

Number of Products by Stage and Molecule Types, H1 2016 31

List of Tables

Number of Products under Development for Polycythemia Vera, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Development, H1 2016 12

Products under Development by Companies, H1 2016 13

Polycythemia Vera-Pipeline by Bristol-Myers Squibb Company, H1 2016 14

Polycythemia Vera-Pipeline by Galena Biopharma, Inc., H1 2016 15

Polycythemia Vera-Pipeline by Gilead Sciences, Inc., H1 2016 16

Polycythemia Vera-Pipeline by Italfarmaco S.p.A., H1 2016 17

Polycythemia Vera-Pipeline by Karus Therapeutics Limited, H1 2016 18

Polycythemia Vera-Pipeline by Merck & Co., Inc., H1 2016 19

Polycythemia Vera-Pipeline by miRagen Therapeutics, Inc., H1 2016 20

Polycythemia Vera-Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 21

Polycythemia Vera-Pipeline by Novartis AG, H1 2016 22

Polycythemia Vera-Pipeline by PharmaEssentia Corporation, H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Stage and Target, H1 2016 26

Number of Products by Stage and Mechanism of Action, H1 2016 28

Number of Products by Stage and Route of Administration, H1 2016 30

Number of Products by Stage and Molecule Type, H1 2016 32

Polycythemia Vera Therapeutics-Recent Pipeline Updates, H1 2016 56

Polycythemia Vera-Dormant Projects, H1 2016 67

Polycythemia Vera-Discontinued Products, H1 2016 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bristol-Myers Squibb Company

Galena Biopharma, Inc.

Gilead Sciences, Inc.

Italfarmaco S.p.A.

Karus Therapeutics Limited

Merck & Co., Inc.

miRagen Therapeutics, Inc.

Nerviano Medical Sciences S.r.l.

Novartis AG

PharmaEssentia Corporation

Polycythemia Vera Therapeutic Products under Development, Key Players in Polycythemia Vera Therapeutics, Polycythemia Vera Pipeline Overview, Polycythemia Vera Pipeline, Polycythemia Vera Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com